Imagene

Company Overview

Snapshot

Founded in January 2020 by Dean Bitan, Shahar Porat, and Jonathan Zalach, Imagene operates with 11–50 employees. The company has raised $44.5M across three funding rounds from six investors.

Business overview

Imagene is an AI-driven company focused on leveraging artificial intelligence to provide real-time molecular profiling from biopsy images. Its core technology classifies patterns invisible to the human eye, integrating genomics, proteomics, and spatial insights for rapid and accurate cancer diagnostics. The company's solutions, including LungOI and CanvOI, aim to overcome economic, logistical, and technological barriers in precision medicine, enabling better patient stratification for clinical trials and the discovery of new drug targets. Imagene serves the healthcare and life sciences sectors, collaborating with medical centers and pharmaceutical companies to revolutionize molecular screening for both clinical practice and research.

Strategic signal

In September 2024, Imagene launched its CanvOI model, powered by Oracle Cloud, to advance cancer treatment. This development signals a strategic move towards leveraging cloud infrastructure for scalable AI solutions in oncology, indicating a focus on expanding access to its molecular profiling technology and strengthening its position in precision medicine.

Company Intelligence Q&A

What is Imagene's primary mission?

Imagene's mission is to leverage AI for real-time profiling of a broad range of biomarkers from biopsy images, aiming to overcome barriers in precision medicine for cancer patients.

When did Imagene launch its CanvOI model?

In September 2024, Imagene launched the CanvOI model, which is powered by Oracle Cloud, to advance cancer treatment.

What recognition did Imagene receive in October 2023?

In October 2023, Imagene won the 2023 Digital Health Awards for "Best use of AI in Health Tech" at the 5th annual Digital Health Hub Foundation Awards.

What was a key development for Imagene's LungOI product in May 2024?

In May 2024, Imagene advanced the commercialization of LungOI with a new payment code and pricing, complementing its existing CLIA Certified US Lab.

Which investor led Imagene's Series B funding round in July 2025?

In July 2025, Larry Ellison led Imagene's Series B funding round, which raised $23 million. This round was also supported by Aguras.